Menarini launches anti-anginal Ranexa in UK and Germany
This article was originally published in Scrip
Executive Summary
CV Therapeutics and Menarini have launched their first-in class anti-anginal Ranexa (ranolazine extended-release tablets) in the UK and Germany, as an adjunctive therapy for patients with stable angina pectoris that are inadequately controlled or intolerant to first-line therapies.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.